{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"8"}],"units":"Participants"}],"description":"Number of participants whose human papillomavirus (HPV) genotypes present at study entry become undetectable without surgical intervention. HPV genotyping detects strains of HPV present at each timepoint. For this outcome, we evaluated whether strains of HPV detected at study entry became undetectable during the study participation.","groups":[{"description":"Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).\n\nArtesunate Suppositories","id":"OG000","title":"50 mg Artesunate Suppositories, 1 Cycle"},{"description":"Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).\n\nArtesunate Suppositories","id":"OG001","title":"200 mg Artesunate Suppositories, 1 Cycle"},{"description":"Subjects enrolled in this cohort will receive 2 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).\n\nArtesunate Suppositories","id":"OG002","title":"200 mg Artesunate Suppositories,2 Cycles"},{"description":"Subjects enrolled in this cohort will receive 3 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).\n\nArtesunate Suppositories","id":"OG003","title":"200 mg Artesunate Suppositories,3 Cycles"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Subjects enrolled in the study who received at least one dose of the investigational drug, and on whom we have outcomes data. 2 participants did not have data collected for this outcome.","reportingStatus":"POSTED","timeFrame":"41 weeks","title":"Viral Clearance of HPV","type":"SECONDARY","unitOfMeasure":"Participants"}